ConductScience.org, home

Paper8533995

An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group.

Ann Intern Med, 1996. Cited by 132 papers, by iCite.

Cite this record

ConductScience Library. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group. Papers, record 8533995. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8533995

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group.
PubMed
Journal
Ann Intern Med
PubMed
Year
1996
PubMed
Publication types
Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
132
iCite
Relative citation ratio, by iCite
4.73
iCite
Revised in PubMed
2019-06-19
PubMed

Topics19

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Aminosalicylic AcidsMajor topic
Anti-Inflammatory Agents, Non-SteroidalMajor topic
Colitis, UlcerativeMajor topic
Adult
Double-Blind Method
Drug Therapy, Combination
Female
Humans
Hydrogen-Ion Concentration
Intestinal Absorption
Male
Mesalamine
Patient Compliance
Polymers
Remission Induction
Sulfasalazine
Tablets, Enteric-Coated
Time Factors
Treatment Outcome

Source PubMed

Download CSV of topics

Cited by36

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 132 citations.

PMIDTitleJournalYearIn PapersSource
41567252Long-Term Efficacy and Safety of Multi-Matrix Mesalazine Maintenance Therapy in Pediatric Patients with Ulcerative Colitis.Pediatr Gastroenterol Hepatol Nutr2026https://conductscience.org/library/papers/41567252PubMed
40955556Clinical Trial: Evaluating a Single 1600 mg Tablet Regimen of 5-Aminosalicylate for Ulcerative Colitis-The EASI Trial.Aliment Pharmacol Ther2025https://conductscience.org/library/papers/40955556PubMed
39990515A practical approach to positioning therapies in ulcerative colitis.J Can Assoc Gastroenterol2025https://conductscience.org/library/papers/39990515PubMed
39129949Patient Preferences for Ulcerative Colitis Treatment in the Middle East Region: A Discrete-Choice Experiment.Gastro Hep Adv2024https://conductscience.org/library/papers/39129949PubMed
36375794De-escalation of Therapy in Patients with Quiescent Inflammatory Bowel Disease.Gut Liver2023https://conductscience.org/library/papers/36375794PubMed
34725785Optimal Placement of Colectomy in the Treatment of Ulcerative Colitis: a Markov Model Analysis.J Gastrointest Surg2021https://conductscience.org/library/papers/34725785PubMed
34511961Patient Preference and Adherence to Aminosalicylates for the Treatment of Ulcerative Colitis.Clin Exp Gastroenterol2021https://conductscience.org/library/papers/34511961PubMed
32856298Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.Cochrane Database Syst Rev2020https://conductscience.org/library/papers/32856298PubMed
30727712Adherence to Asacol once daily versus divided regimen for maintenance therapy in ulcerative colitis: a prospective, multicenter, randomized study.Intest Res2019https://conductscience.org/library/papers/30727712PubMed
28886205Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis.Cochrane Database Syst Rev2017https://conductscience.org/library/papers/28886205PubMed
28670233Comparison of efficacies of once-daily dose multimatrix mesalazine and multiple-dose mesalazine for the maintenance of remission in ulcerative colitis: a randomized, double-blind study.Intest Res2017https://conductscience.org/library/papers/28670233PubMed
28239313Second Korean guidelines for the management of ulcerative colitis.Intest Res2017https://conductscience.org/library/papers/28239313PubMed
27158764Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.Cochrane Database Syst Rev2016https://conductscience.org/library/papers/27158764PubMed
26269667Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2.World J Gastroenterol2015https://conductscience.org/library/papers/26269667PubMed
26199624Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug Withdrawal.Gastroenterol Res Pract2015https://conductscience.org/library/papers/26199624PubMed
24127239Assessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative data.Patient2013https://conductscience.org/library/papers/24127239PubMed
23363459Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database.BMC Gastroenterol2013https://conductscience.org/library/papers/23363459PubMed
22720120Endoscopy in inflammatory bowel disease when and why.World J Gastrointest Endosc2012https://conductscience.org/library/papers/22720120PubMed
22390554Mesalamine in the treatment and maintenance of remission of ulcerative colitis.Expert Rev Clin Pharmacol2012https://conductscience.org/library/papers/22390554PubMed
21904481A new look at a mainstay ulcerative colitis therapy.Gastroenterol Hepatol (N Y)2008https://conductscience.org/library/papers/21904481PubMed

See all 36 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Authors
  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/8533995

GET https://conductscience.org/api/papers/v1/8533995/cited_by?page=2